Portal Access, Inc. Secures $7 Million Funding to Advance Chemotherapy Device to FDA Approval
Portal Access, Inc., a pioneering medical device company dedicated to improving vascular access solutions for cancer patients, has announced the successful completion of a $7 million Series A financing round. This significant milestone demonstrates the strong support from investors, which includes a notable involvement of over 80% from U.S.-based physician investors such as oncologists, interventional radiologists, and vascular surgeons. The enthusiasm from these medical professionals underscores the confidence in the company's vision for transforming cancer care through innovative technology.
The funding will primarily be channeled towards regulatory activities and the submission of a 510(k) application to the U.S. Food and Drug Administration (FDA) for the Flexi-Port™ SLF-TANL™ device. This novel subcutaneous port is designed to streamline vascular access for oncology patients, simplifying the process while enhancing usability and reducing associated complexities. The 510(k) submission is projected for July 2025, with the market launch anticipated in early 2026.
Dr. Michael Tal, the Founder and CEO of Portal Access, highlighted the importance of this funding in achieving regulatory approval. He emphasized that the Flexi-Port™ SLF-TANL™ is engineered for simplicity, stability, and scalability—attributes expected to support more efficient workflows in oncology settings. This device not only aims to enhance the clinician's experience but also focuses significantly on improving patient outcomes.
Despite being a common aspect of cancer treatment, many patients do not receive chemotherapy ports due to delays in treatment and other barriers. With the introduction of the Flexi-Port™ SLF-TANL™, Portal Access aims to minimize these hurdles, potentially reducing treatment delays and procedural risks, while also lowering overall healthcare costs. By enhancing accessibility, the device is positioned to improve the experience for both healthcare providers and patients across the board in cancer care.
Matthew Ostroff, an esteemed RN with extensive experience in bedside vascular access, expressed his support for the Flexi-Port SLF-TANL™, noting its effectiveness and the innovative self-tunneling technology. He stressed that this less invasive option could revolutionize port placement practices, providing a more compassionate and dignified experience for patients during critical moments in their treatment.
The investment round garnered remarkable attention, particularly from individual physician investors, who contributed approximately $6 million to the funding. Angela Dotson, the Executive VP of Business Development at Portal Access, expressed her excitement about this unprecedented level of interest. She noted that the acute demand from clinics and hospitals nationwide illustrates the long-standing anticipation for a technological advancement like the Flexi-Port™ SLF-TANL™.
In summary, the completion of this funding round is a pivotal step toward the introduction of the Flexi-Port™ SLF-TANL™. The device is committed to making chemotherapy treatment more accessible and efficient, fundamentally transforming the standard care delivery process in oncology. Portal Access, Inc. directs its efforts towards finalizing regulatory approvals and launching this innovative solution, which has the potential to greatly enhance the treatment journey for cancer patients.
Portal Access, Inc. is dedicated to designing solutions that aim to minimize the complications associated with chemotherapy port placements. The Flexi-Port™ SLF-TANL™ is currently not available for purchase, but the company plans to share further updates as they move closer to market launch.
The funding will primarily be channeled towards regulatory activities and the submission of a 510(k) application to the U.S. Food and Drug Administration (FDA) for the Flexi-Port™ SLF-TANL™ device. This novel subcutaneous port is designed to streamline vascular access for oncology patients, simplifying the process while enhancing usability and reducing associated complexities. The 510(k) submission is projected for July 2025, with the market launch anticipated in early 2026.
Dr. Michael Tal, the Founder and CEO of Portal Access, highlighted the importance of this funding in achieving regulatory approval. He emphasized that the Flexi-Port™ SLF-TANL™ is engineered for simplicity, stability, and scalability—attributes expected to support more efficient workflows in oncology settings. This device not only aims to enhance the clinician's experience but also focuses significantly on improving patient outcomes.
Despite being a common aspect of cancer treatment, many patients do not receive chemotherapy ports due to delays in treatment and other barriers. With the introduction of the Flexi-Port™ SLF-TANL™, Portal Access aims to minimize these hurdles, potentially reducing treatment delays and procedural risks, while also lowering overall healthcare costs. By enhancing accessibility, the device is positioned to improve the experience for both healthcare providers and patients across the board in cancer care.
Matthew Ostroff, an esteemed RN with extensive experience in bedside vascular access, expressed his support for the Flexi-Port SLF-TANL™, noting its effectiveness and the innovative self-tunneling technology. He stressed that this less invasive option could revolutionize port placement practices, providing a more compassionate and dignified experience for patients during critical moments in their treatment.
The investment round garnered remarkable attention, particularly from individual physician investors, who contributed approximately $6 million to the funding. Angela Dotson, the Executive VP of Business Development at Portal Access, expressed her excitement about this unprecedented level of interest. She noted that the acute demand from clinics and hospitals nationwide illustrates the long-standing anticipation for a technological advancement like the Flexi-Port™ SLF-TANL™.
In summary, the completion of this funding round is a pivotal step toward the introduction of the Flexi-Port™ SLF-TANL™. The device is committed to making chemotherapy treatment more accessible and efficient, fundamentally transforming the standard care delivery process in oncology. Portal Access, Inc. directs its efforts towards finalizing regulatory approvals and launching this innovative solution, which has the potential to greatly enhance the treatment journey for cancer patients.
Portal Access, Inc. is dedicated to designing solutions that aim to minimize the complications associated with chemotherapy port placements. The Flexi-Port™ SLF-TANL™ is currently not available for purchase, but the company plans to share further updates as they move closer to market launch.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.